Signal Pharmaceuticals, Inc.

New York University

Weilin Xie

Frank Mercurio

Michele Pagano

Antonia Lopez-Girona

Heather K Raymon

Brian Edwin Cathers

Brydon L Bennett

Jeffrey McKenna

Brion William Murray

Veronique Plantevin

Angelo Peschiaroli

Kristen Lee Jensen-Pergakes

Jaman May Maroni

Merl F Hoekstra

Provided herein are Aminopurine Compounds having the following structure: wherein R, Rand Rare as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing scleroderma, keloids, UV injury, or sunburn, and methods for improving or preventing scar formation.

Methods of treatment, improvement and prevention using haloaryl substituted aminopurines

The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits. The present invention relates to screening assays that use novel and known substrate-targeting subunits of ubiquitin ligases to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel and known ubiquitin ligases which modulate activity of the novel and known ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative and differentiative disorders.

Methods to identify compounds useful for the treatment of proliferative and differentiative disorders

Methods are provided for identifying agents that modulate signaling mediated by transforming growth factor beta (TGF-&#x3b2;) and members of the TGF-&#x3b2; family, such as bone morphogenic protein (BMP). Such agents may be identified using screens that evaluate candidate agents for the ability to modulate Smad protein degradation. Agents identified as described herein may be used to augment or inhibit signaling mediated by one or more TGF-&#x3b2; family members in a variety of cell types and for therapeutic purposes.

Methods for modulating signal transduction mediated by TGF-&#x3b2; and related proteins

The present invention generally relates to compounds and compositions useful for the modulation of ligase activity. The invention further relates to Compounds of the Invention, compositions thereof, and methods for treating or preventing cancer, a neoplastic disorder, acute or chronic renal failure, an inflammatory disorder, an immune disorder, a cardiovascular disease, an effect of aging or an infectious disease comprising administering an effective amount of a Compound of the Invention. The invention further relates to the use of a Compound of the Invention as a preservative of a cell, blood, tissue or an organ or as an agent to modulate stem cells.

Compounds useful for the treatment of cancer, compositions thereof and methods therewith

Growing community of inventors

San Diego, CA, United States of America

Weilin Xie